FR14C0017I2 - NEW SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS - Google Patents

NEW SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS

Info

Publication number
FR14C0017I2
FR14C0017I2 FR14C0017C FR14C0017C FR14C0017I2 FR 14C0017 I2 FR14C0017 I2 FR 14C0017I2 FR 14C0017 C FR14C0017 C FR 14C0017C FR 14C0017 C FR14C0017 C FR 14C0017C FR 14C0017 I2 FR14C0017 I2 FR 14C0017I2
Authority
FR
France
Prior art keywords
sulfamides
new
receptor antagonists
endothelin receptor
endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0017C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of FR14C0017I2 publication Critical patent/FR14C0017I2/en
Publication of FR14C0017I1 publication Critical patent/FR14C0017I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR14C0017C 2000-12-18 2014-03-03 NEW SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS Active FR14C0017I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0012890 2000-12-18
PCT/EP2001/014182 WO2002053557A1 (en) 2000-12-18 2001-12-04 Novel sulfamides and their use as endothelin receptor antagonists

Publications (2)

Publication Number Publication Date
FR14C0017I2 true FR14C0017I2 (en) 2014-11-14
FR14C0017I1 FR14C0017I1 (en) 2021-08-27

Family

ID=8164206

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0017C Active FR14C0017I2 (en) 2000-12-18 2014-03-03 NEW SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS

Country Status (27)

Country Link
US (2) US7094781B2 (en)
EP (2) EP1345920B1 (en)
JP (1) JP4245130B2 (en)
KR (1) KR100819668B1 (en)
CN (1) CN100432070C (en)
AR (1) AR035610A1 (en)
AT (1) ATE323079T1 (en)
AU (1) AU2002227984B8 (en)
BE (1) BE2014C019I2 (en)
BR (1) BRPI0116237B8 (en)
CA (1) CA2431675C (en)
CY (2) CY1105060T1 (en)
DE (1) DE60118782T2 (en)
DK (1) DK1345920T3 (en)
ES (1) ES2260318T3 (en)
FR (1) FR14C0017I2 (en)
HU (1) HU229403B1 (en)
IL (2) IL155805A0 (en)
LU (1) LU92381I2 (en)
MX (1) MXPA03004780A (en)
MY (1) MY129150A (en)
NL (1) NL300672I2 (en)
NO (2) NO324952B1 (en)
NZ (1) NZ525614A (en)
PT (1) PT1345920E (en)
WO (1) WO2002053557A1 (en)
ZA (1) ZA200303695B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1345920B1 (en) * 2000-12-18 2006-04-12 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
EP2198867A1 (en) 2001-12-07 2010-06-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
NZ540937A (en) * 2002-12-02 2008-06-30 Actelion Pharmaceuticals Ltd Pyrimidine-sulfamides and their use as endothelian receptor antagonist
EP1725540B1 (en) 2004-03-05 2012-09-12 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
UA90269C2 (en) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Tetrahydroquinoline derivatives and a process for preparing the same
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
MY142972A (en) 2005-07-29 2011-01-31 Tibotec Pharm Ltd Macrocyclic inhibitors of hepatitis c virus
ES2373685T3 (en) 2005-07-29 2012-02-07 Tibotec Pharmaceuticals MACROCYCLIC INHIBITORS OF HEPATITIS VIRUS C.
CN101253159B (en) 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 Diaminopyrimidines as P2X3 and P2X2/3 modulators
CA2619919C (en) * 2005-09-01 2014-04-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025901A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ES2393117T3 (en) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine sulfamide
AR062501A1 (en) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd THERAPEUTIC COMPOSITIONS
MX2010001837A (en) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Iron with actively cooled soleplate and method for cooling the soleplate.
EP2199283A1 (en) 2007-09-27 2010-06-23 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for anemia, comprising tetrahydroquinoline compound as active ingredient
WO2009104149A1 (en) * 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Combination comprising paclitaxel for treating ovarian cancer
DK3300729T3 (en) 2008-08-13 2020-01-20 Actelion Pharmaceuticals Ltd THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN
JP5572154B2 (en) 2009-03-31 2014-08-13 興和株式会社 A prophylactic and / or therapeutic agent for anemia comprising a tetrahydroquinoline compound as an active ingredient
EP2464218B1 (en) * 2009-08-10 2015-05-27 Board of Regents, The University of Texas System Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
EP3205647B1 (en) 2009-08-17 2020-05-13 Memorial Sloan-Kettering Cancer Center 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders
WO2011078143A1 (en) * 2009-12-22 2011-06-30 塩野義製薬株式会社 Pyrimidine derivatives and pharmaceutical composition containing same
AU2012213036A1 (en) * 2011-02-04 2013-09-19 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme
KR20150128863A (en) * 2013-03-15 2015-11-18 에프. 호프만-라 로슈 아게 ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS
AR095727A1 (en) * 2013-03-27 2015-11-04 Actelion Pharmaceuticals Ltd PREPARATION OF PYRIMIDINE INTERMEDIARIES
DE14721256T1 (en) 2013-04-22 2017-03-16 Sandoz Ag PHARMACEUTICAL COMPOSITIONS WITH CRYSTALLINE MACITENTANE
CN104411691B (en) * 2013-06-14 2016-05-25 杭州普晒医药科技有限公司 ACT-064992 crystal and preparation method thereof, its pharmaceutical composition and purposes
AR096865A1 (en) * 2013-07-12 2016-02-03 Actelion Pharmaceuticals Ltd PROCESS FOR THE PREPARATION OF A PYRIMIDINE INTERMEDIARY
CN103724281A (en) * 2013-12-03 2014-04-16 镇江圣安医药有限公司 Novel derivative of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propyl and application of novel derivative
EP2907811A1 (en) * 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
CN103819411A (en) * 2014-03-14 2014-05-28 成都克莱蒙医药科技有限公司 New preparation method of macitentan intermediate
MX2016014755A (en) 2014-05-13 2017-03-27 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same.
EP3169669A1 (en) * 2014-07-15 2017-05-24 OLON S.p.A. Amorphous form and new crystalline forms of macitentan
CN104447572A (en) * 2014-12-15 2015-03-25 南京艾德凯腾生物医药有限责任公司 Method for preparing macitentan
WO2016203489A1 (en) 2015-06-15 2016-12-22 Megafine Pharma (P) Ltd. Process for the preparation of macitentan and intermediates thereof
ZA201605808B (en) 2015-08-26 2017-08-30 Cipla Ltd Process for preparing an endothelin receptor antagonist
CN105461639B (en) * 2015-12-10 2018-03-09 合肥久诺医药科技有限公司 A kind of process for purification of high-purity ACT-064992
CN105388244B (en) * 2015-12-10 2017-03-08 合肥久诺医药科技有限公司 A kind of ACT-064992 is about the HPLC (high performance liquid chromatography) of material
WO2017191565A1 (en) * 2016-05-04 2017-11-09 Shilpa Medicare Limited Process for preparation of macitentan
CN107868055B (en) 2016-09-28 2020-02-07 普济生物科技（台州）有限公司 Preparation method of macitentan
CN106478522A (en) * 2016-10-11 2017-03-08 合肥久诺医药科技有限公司 A kind of preparation method of ACT-064992 contamination levels product
CN106478520B (en) * 2016-10-11 2018-09-11 合肥久诺医药科技有限公司 A kind of synthetic method of macitentan contamination levels product
SG11201907435PA (en) 2017-02-27 2019-09-27 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
CN110506040A (en) 2017-04-03 2019-11-26 先正达参股股份有限公司 Kill the oxadiazole derivatives of microorganism
CN107141238A (en) * 2017-06-16 2017-09-08 吴宁怡 A kind of preparation method of ACT-064992 intermediate
EP3719013B1 (en) * 2017-11-21 2023-01-04 Wuxi Biocity Biopharmaceutics Co., Ltd. Pyrimidine sulfamide derivative and preparation method and medical application thereof
MX2020005543A (en) 2017-11-30 2020-08-20 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases.
CN108653292B (en) * 2018-07-03 2019-05-24 中国人民解放军总医院 A kind of compound is treating or preventing the purposes in altitude sickness
CN108997223B (en) * 2018-08-09 2020-06-30 浙江先锋科技股份有限公司 Preparation method of 5- (4-bromophenyl) -4, 6-dichloropyrimidine
CN109232546B (en) 2018-09-25 2020-09-04 中国人民解放军总医院 Medical application of pyrimidine sulfonamide derivative
SG11202105098VA (en) 2018-12-21 2021-06-29 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (en) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 Pharmaceutical composition for the treatment of chronic thromboembolic pulmonary hypertension
TW202103703A (en) 2019-04-05 2021-02-01 瑞士商艾克泰聯製藥有限公司 Methods for treating portopulmonary hypertension
EP3974421B1 (en) * 2019-05-22 2024-09-11 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystal form of pyrimidine sulfonamide compound and preparation method therefor
US20220249381A1 (en) 2019-07-05 2022-08-11 TECNIMEDE - Sociedade Técnico-medicinal, SA Compressed macitentan compositions, methods and uses thereof
TW202133851A (en) 2019-11-29 2021-09-16 瑞士商艾克泰聯製藥有限公司 Methods of treating pulmonary arterial hypertension
WO2022258796A1 (en) 2021-06-11 2022-12-15 Actelion Pharmaceuticals Ltd Dispersible tablet for oral administration
EP4154873A1 (en) 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan
WO2023227490A1 (en) 2022-05-22 2023-11-30 Idorsia Pharmaceuticals Ltd Aprocitentan for the treatment of hypertension
WO2023227721A1 (en) 2022-05-25 2023-11-30 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide
WO2024099953A1 (en) 2022-11-07 2024-05-16 Actelion Pharmaceuticals Ltd Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801584A1 (en) * 1978-01-14 1979-07-19 Bayer Ag HALOGEN-SUBSTITUTED PYRIMIDIN (2) YL-THIONO-THIOL-PHOSPHOR (PHOSPHONE) - ACID ESTERS, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS INSECTICIDES AND ACARICIDES
US5132373A (en) * 1990-08-13 1992-07-21 General Electric Company Ortho ester-capped polyphenylene ethers and copolymers prepared therefrom
RU2086544C1 (en) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
US5324796A (en) * 1992-12-02 1994-06-28 General Electric Company Polyarylene sulfide and epoxy-functionalized siloxane blends
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5523204A (en) 1993-12-10 1996-06-04 Becton Dickinson And Company Detection of nucleic acids in cells by strand displacement amplification
WO1996016963A1 (en) * 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamides and their use as medicaments
TW313568B (en) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
JP3087968B2 (en) 1995-12-20 2000-09-18 山之内製薬株式会社 Arylethenesulfonamide derivatives and pharmaceutical compositions thereof
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
NZ512526A (en) * 1999-09-03 2004-01-30 Actelion Pharmaceuticals Ltd 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
AU3536701A (en) * 1999-12-22 2001-07-03 Actelion Pharmaceuticals Ltd Butyne diol derivatives
AU2001263850A1 (en) * 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
EP1345920B1 (en) * 2000-12-18 2006-04-12 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists

Also Published As

Publication number Publication date
CY2014017I1 (en) 2015-12-09
AU2002227984A1 (en) 2002-07-16
PT1345920E (en) 2006-08-31
BE2014C019I2 (en) 2021-01-29
HUP0301654A2 (en) 2007-03-28
WO2002053557A1 (en) 2002-07-11
BR0116237A (en) 2003-09-30
JP4245130B2 (en) 2009-03-25
HUP0301654A3 (en) 2007-08-28
US20040077670A1 (en) 2004-04-22
ZA200303695B (en) 2004-08-13
MY129150A (en) 2007-03-30
ES2260318T3 (en) 2006-11-01
DE60118782T2 (en) 2007-01-25
EP1345920A1 (en) 2003-09-24
US7094781B2 (en) 2006-08-22
CN1524079A (en) 2004-08-25
CY1105060T1 (en) 2010-03-03
KR100819668B1 (en) 2008-04-04
US7285549B2 (en) 2007-10-23
BRPI0116237B1 (en) 2016-08-09
CY2014017I2 (en) 2015-12-09
NZ525614A (en) 2005-03-24
EP1693372A1 (en) 2006-08-23
NO20032699L (en) 2003-06-13
NL300672I2 (en) 2016-10-11
FR14C0017I1 (en) 2021-08-27
NO324952B1 (en) 2008-01-14
US20060178365A1 (en) 2006-08-10
ATE323079T1 (en) 2006-04-15
EP1345920B1 (en) 2006-04-12
CN100432070C (en) 2008-11-12
NO20032699D0 (en) 2003-06-13
BRPI0116237B8 (en) 2021-05-25
LU92381I2 (en) 2014-04-28
MXPA03004780A (en) 2004-05-21
AU2002227984B8 (en) 2007-01-04
IL155805A0 (en) 2003-12-23
CA2431675C (en) 2011-11-08
DK1345920T3 (en) 2006-08-14
JP2004517855A (en) 2004-06-17
AR035610A1 (en) 2004-06-16
KR20030066713A (en) 2003-08-09
NO2014014I2 (en) 2015-08-31
HU229403B1 (en) 2013-12-30
AU2002227984B2 (en) 2006-12-07
DE60118782D1 (en) 2006-05-24
IL155805A (en) 2009-02-11
CA2431675A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
FR14C0017I2 (en) NEW SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
MA25829A1 (en) CARBOXAMIDE COMPOUNDS AND THEIR USE AS HUMAN CBY II RECEPTOR ANTAGONISTS
ATE368659T1 (en) THROMBIN RECEPTOR ANTAGONISTS
FR15C0049I2 (en) 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
DE50004975D1 (en) cantilever parasol
MA26773A1 (en) 3-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 ANTAGONIST RECEPTORS
ATE400558T1 (en) METABOTROPIC GLUTAMA RECEPTOR ANTAGONISTS
AU6031001A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
DE60135231D1 (en) COMPOSITE NONWOVEN
DE69812096D1 (en) NEUROPEPTID Y RECEPTOR ANTAGONISTS
SI1170288T1 (en) Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists
EP1327713A4 (en) Multilayer non-woven fabric and use thereof
DE60114413D1 (en) SUBSTITUTED 1-AMINOALKYL-LACTAME AND THEIR USE AS MUSCARIN RECEPTOR ANTAGONISTS
DZ3361A1 (en) BICYCLIC CYCLOHEXYLAMINES AND THEIR USE AS ANTAGONISTS OF NMDA RECEPTORS
TR199701645A3 (en) Vitronectin receptor antagonists, their manufacture and use
DE69823694D1 (en) THROMBIN RECEPTOR ANTAGONISTS
NO20000542L (en) Endothelin antagonists
MA26776A1 (en) 4-HETEROCYCLYSULFONAMIDYL-6- METHOXY-5- (2-METHOXYPHENOXY) -2-PYRIDYL PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
DZ3333A1 (en) IL-8 RECEPTOR ANTAGONISTS
DE60130000D1 (en) TWITTER TACHYKININE RECEPTOR ANTAGONISTS
AU3958902A (en) Crf receptor antagonists and methods relating thereto
GB0011817D0 (en) Antagonists of integrin receptors
MA28642B1 (en) CRYSTALLINE FORMS OF PYRIDINYL-SULFONAMIDE AND THEIR USE AS ANTAGONISTS OF ENDOTHELIN RECEPTORS
PT1448566E (en) CHEMICOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
NO20015237L (en) Integrin antagonists